• Locations
  • Conditions
  • Treatments
  • Institutions
  • Resources
  • For researchers
  • About us
Facebook link logoLinkedin link logo
Terms of usePrivacy policy
All Clinical Trials 2026All Rights reservedPrivacy PolicyTerms of Use
LocationsTexasArizonaCaliforniaNew YorkMassachusettsFloridaNew JerseyUtahAll locationsConditionsOncologyAlzheimer'sDiabetesMultiple SclerosisArthritisHepatitis CCOPDDepressionAll conditionsTreatmentsWeight LossStem CellsVaccinesSleep ApneaMedical DevicesIVFDentalDrug AddictionAll treatmentsInstitutionsPfizerModernaNIHUCLAStanfordM.D. AndersonLabcorpAll institutionsResourcesBlogFAQMedical advisors
Terms of usePrivacy policy
All Clinical Trials 2026All Rights reservedPrivacy PolicyTerms of Use
  1. Clinical trials
  2. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
  3. Apply

CPX-351 & GilteritinibA Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Basic information
Step 1/5

Provide your basic information